{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:54:49Z","timestamp":1649202889130},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Zusammenfassung<\/jats:title>\n Einleitung Die HIV-PrEP (HIV-Pr\u00e4-Expositionsprophylaxe) ist seit\n 2017 \u00fcber deutsche Apotheken in unterschiedlichen Abpackungen\n erh\u00e4ltlich. Sie ist entweder als t\u00e4gliche Einnahme oder als\n intermittierende, anlassbezogene Einnahme anwendbar.<\/jats:p>\n Fragestellung Es sollten soziodemografische Basischarakteristika, die\n Vorgeschichte hinsichtlich STIs (sexual transmitted infections), der\n fr\u00fcheren PEP-Einnahme, das Schema der PrEP-Einnahme, die erfolgte\n Vordiagnostik sowie die Beratung zur PrEP-Einnahme und Angaben zur Weitergabe\n von PrEP erfasst werden.<\/jats:p>\n Methodik Es wurde eine Querschnittsanalyse in Form eines revidierten,\n selbstentwickelten Multiple-Choice-Fragebogens bei 515 Nutzern im Netzwerk\n HIV-kompetenter Apotheken durchgef\u00fchrt.<\/jats:p>\n Ergebnisse Die ausschlie\u00dflich m\u00e4nnlichen Teilnehmer\n befinden sich zu 3\/4 in der Altersgruppe 20\u201339 Jahre.\n \u00dcber 80% der Nutzer wenden die PrEP gem\u00e4\u00df\n Zulassung an. Etwa 2\/3 hatten in fr\u00fcheren Jahren eine PEP\n (Post-Expositionsprophylaxe) erhalten. Die gleiche Anzahl hatte in\n fr\u00fcheren Jahren mindestens eine STI. Die notwendige Vordiagnostik wurde\n \u00fcberwiegend durchgef\u00fchrt. Die PrEP wird von 7% an andere\n Anwender weitergegeben.<\/jats:p>\n Schlussfolgerung Die Mehrheit (etwa 2\/3) der PrEP Nutzer sind\n Hochrisiko-Anwender bezogen auf vorherige STIs (sexual transmitted infections)\n oder fr\u00fchere PEP-Anwendung), der \u00fcberwiegende Anteil nutzt die\n PrEP zulassungsgem\u00e4\u00df. Der Stellenwert der PrEP wird in der\n Zukunft durch einfachere Verordnungsf\u00e4higkeit und breitere Anwendung\n weiter wachsen.<\/jats:p>","DOI":"10.1055\/a-1162-8308","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T22:45:15Z","timestamp":1599518715000},"page":"1015-1018","source":"Crossref","is-referenced-by-count":0,"title":["Nutzerseitige Adh\u00e4renz und Off-Label-Use der\n HIV-Pr\u00e4-Expositionsprophylaxe"],"prefix":"10.1055","volume":"83","author":[{"given":"Christian","family":"Fl\u00f6ssner","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Allgemeinmedizin, Medizinische Fakult\u00e4t,\n Martin-Luther-Universit\u00e4t Halle-Wittenberg, Halle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin T.","family":"Schleenvoigt","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Infektionsmedizin und Krankenhaushygiene,\n Universit\u00e4tsklinikum Jena, Jena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Abendroth","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Allgemeinmedizin, Medizinische Fakult\u00e4t,\n Martin-Luther-Universit\u00e4t Halle-Wittenberg, Halle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Frese","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Allgemeinmedizin, Medizinische Fakult\u00e4t,\n Martin-Luther-Universit\u00e4t Halle-Wittenberg, Halle"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"ref14","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in\n men who have sex with men","volume":"4","author":"P L Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a\n clinical trial of PrEP for HIV prevention","volume":"66","author":"D Donnell","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr. JAIDS Journal of Acquired Immune\n Deficiency Syndromes"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"J-M Molina","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"ref20","first-page":"2587","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with\n men","volume":"27","author":"R M Grant","year":"2010","journal-title":"In: N. Engl. J. Med. 363, Nr"},{"key":"ref23","first-page":"2587","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with\n men","volume":"27","author":"R M Grant","year":"2010","journal-title":"In: N. Engl. J. Med. 363, Nr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e00206617","DOI":"10.1590\/0102-311X00206617","article-title":"Equipe do Estudo Combina!. [From evidence to action: challenges for the\n Brazilian Unified National Health System in offering pre-exposure prophylaxis\n (PrEP) for HIV to persons with the greatest vulnerability]","volume":"34","author":"E M Zucchi","year":"2018","journal-title":"Cad Saude Publica"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1071\/SH18103","article-title":"Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges\n and emerging models of PrEP implementation","volume":"15","author":"P S Sullivan","year":"2018","journal-title":"Sex Health"},{"key":"ref30","first-page":"151","article-title":"HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral\n systemic HIV PrEP in humans. Infection","volume":"44","author":"C D Spinner","year":"2016","journal-title":"Springer Berlin Heidelberg"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/09540121.2016.1146653","article-title":"Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS\n IPERGAY trial","volume":"28","author":"L Sagaon-Teyssier","year":"2016","journal-title":"AIDS Care. Taylor & Francis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"J-M Molina","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s10461-019-02577-7","article-title":"Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A\n Methodological Review","volume":"23","author":"R M Pinto","year":"2019","journal-title":"AIDS Behav"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.idc.2019.04.002","article-title":"Antiretroviral Medications for the Prevention of HIV Infection: A Clinical\n Approach to Preexposure Prophylaxis, Postexposure Prophylaxis, and Treatment as\n Prevention","volume":"33","author":"A Heendeniya","year":"2019","journal-title":"Infect Dis Clin North Am"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1162-8308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:26:33Z","timestamp":1639182393000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1162-8308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1162-8308","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}